Amylin sues Eli Lilly for anticompetitive activity
Amylin Pharmaceuticals has filed a lawsuit against Eli Lilly, alleging that Lilly is engaging in "anticompetitive activity" and "breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide." More... |
| |
J&J recalls select lots of Prezista
Janssen-Cilag International, part of Johnson & Johnson, is working with regulatory authorities in five countries to address the trace amounts of 2,4,6-tribromoanisole (TBA) that were identified in five batches of the HIV–AIDS medicine Prezista (darunavir). More... |
| |
Teva acquires majority stake in Taiyo
Teva Pharmaceutical Industries has agreed to pay shareholders $460 million in cash to acquire a 57% stake in Taiyo Pharmaceutical Industry, Japan’s third-largest manufacturer of generic pharmaceuticals. More... |
| |
FDA approvals of biopharmaceuticals on the rise
Regulatory approvals for new biopharmaceuticals in the US have nearly doubled in the past decade compared with the 1990s, according to a new report from the Tufts Center for the Study of Drug Development.
More... |
| |
PhRMA comments on pharmaceutical trade practices report
The Office of the United States Trade Representative has issued a report that addresses IPR protection and enforcement, and specific initiatives such as measures relating to anticounterfeiting and market access. More... |
| |
US introduces bill on regenerative medicine
A bill has been introduced in the US House of Representatives that seeks to establish funding priorities for the R&D of regenerative medicine products, and to develop a regulatory environment to ensure the rapid approval of safe and effective products. More... |
| |
Join our community on LinkedIn
Want to discuss any of this week's news stories or any other hot topics in the industry? Then why not join our group on LinkedIn? More... |
| |
